Indaptus Therapeutics
INDP
4 hedge funds and large institutions have $93.7K invested in Indaptus Therapeutics in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
62% more capital invested
Capital invested by funds: $57.9K → $93.7K (+$35.7K)
0.03% more ownership
Funds ownership: 1.81% → 1.84% (+0.03%)
20% less funds holding
Funds holding: 5 → 4 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$80.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$55K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$23 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $84.4K | +$80.9K | +28,500 | +5,677% |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $9.17K | +$7.6K | +2,678 | +566% |
|
|
3
Bank of America
Charlotte,
North Carolina
| $73 | -$23 | -8 | -24% |
|
|
SS
4
SBI Securities
Tokyo,
Japan
| $49 | – | – | – |
|
|
VF
5
Virtu Financial
New York
| – | -$55K | -18,997 | Closed |
|
INDP Hedge Fund Activity: Q4 2025 in Review
4 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q4 2025, worth a combined $93.7K — up 62% from $57.9K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of INDP and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was UBS Group, adding an estimated $80.9K. The largest seller was Virtu Financial, exiting entirely with an estimated $55K sold.
- 4 institutional investors held Indaptus Therapeutics (INDP) as of Q4 2025, down from 5 in Q3 2025.
- Funds reported $93.7K of Indaptus Therapeutics stock for Q4 2025, up 62% quarter-over-quarter.
- 0 funds opened new Indaptus Therapeutics positions in Q4 2025 and 1 closed out, a net change of -1 holder.
- The largest Indaptus Therapeutics buyer in Q4 2025 was UBS Group, an estimated $80.9K added.
- The largest Indaptus Therapeutics seller in Q4 2025 was Virtu Financial, an estimated $55K sold.
Based on aggregated 13F filings for Q4 2025.